

# DEGS1 Antibody / DES1 / Dihydroceramide desaturase-1 [clone 30D03] (FY12995)

Catalog No.	Formulation	Size
FY12995	Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium	100 ul
	azide and 50% glycerol, 0.4-0.5mg/ml BSA	

## Recombinant RABBIT MONOCLONAL

## **Bulk quote request**

Availability	2-3 weeks
Species Reactivity	Human
Format	Liquid
Clonality	Recombinant Rabbit Monoclonal
Isotype	Rabbit IgG
Clone Name	30D03
Purity	Affinity-chromatography
Buffer	Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol, 0.4-0.5mg/ml BSA.
UniProt	O15121
Applications	Western Blot : 1:500-1:2000
Limitations	This DEGS1 antibody is available for research use only.

# **Description**

DEGS1 antibody detects Dihydroceramide desaturase 1, encoded by the DEGS1 gene. This enzyme catalyzes the introduction of a trans double bond into dihydroceramide to produce ceramide, a central step in the sphingolipid biosynthesis pathway. Ceramides are essential bioactive lipids involved in regulating apoptosis, autophagy, differentiation, and membrane organization. DEGS1 antibody provides researchers with a valuable tool to study sphingolipid metabolism, cellular signaling, and the pathogenesis of metabolic and neurodegenerative diseases.

Dihydroceramide desaturase 1 resides in the endoplasmic reticulum and is part of a larger network of enzymes controlling sphingolipid levels. By converting dihydroceramide to ceramide, DEGS1 regulates the balance between precursors and bioactive sphingolipids. Research with DEGS1 antibody has shown that altered activity of this enzyme shifts cellular lipid composition, leading to changes in apoptosis sensitivity and membrane structure. Ceramides produced by DEGS1 also participate in signaling pathways that control stress responses, mitochondrial function, and immune activity.

Mutations in DEGS1 cause rare hereditary spastic paraplegia and leukodystrophy, highlighting the enzyme's role in nervous system development and maintenance. Patients with DEGS1 mutations show impaired myelination, progressive neurodegeneration, and developmental delay. Studies using DEGS1 antibody have demonstrated that defective enzyme activity leads to accumulation of dihydroceramides and reduced ceramide production, disrupting neuronal signaling and survival. These findings underscore the enzyme's essential role in neurobiology and its potential as a therapeutic target.

In cancer, altered sphingolipid metabolism has been linked to tumor progression and treatment resistance. DEGS1 contributes to the regulation of apoptosis sensitivity, and reduced ceramide levels can enable survival of malignant cells under stress. Research with DEGS1 antibody has associated aberrant expression with poor prognosis in certain cancers, making it a potential biomarker and therapeutic target. Beyond oncology, sphingolipid imbalance has been implicated in metabolic diseases such as diabetes and obesity, further expanding the relevance of DEGS1.

DEGS1 antibody is applied in western blotting, immunohistochemistry, and lipidomic studies. Western blotting confirms protein expression levels, while immunohistochemistry highlights tissue specific distribution in brain, liver, and metabolic organs. Functional assays using DEGS1 antibody in combination with lipidomics allow researchers to connect enzyme expression with lipid composition changes, providing a systems level view of sphingolipid biology.

By supplying validated DEGS1 antibody reagents, NSJ Bioreagents supports studies of lipid metabolism, neurodegeneration, and cancer biology. Detection of Dihydroceramide desaturase 1 provides a critical tool for understanding how sphingolipid regulation contributes to health and disease.

## **Application Notes**

Optimal dilution of the DEGS1 antibody should be determined by the researcher.

## **Immunogen**

A synthesized peptide derived from human MLD was used as the immunogen for the DEGS1 antibody.

#### **Storage**

Store the DEGS1 antibody at -20oC.